Optimal Use of BRAF Targeting Therapy in the Immunotherapy Era

Current Oncology Reports

Volumn 18, Issue 11, 2016, Pages

  Wood, Kevin ^a   Luke, Jason J ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

BRAF; Dabrafenib; Immunotherapy; MEK; Melanoma; Metastatic; Vemurafenib

Indexed keywords

ATEZOLIZUMAB; B RAF KINASE; B RAF KINASE INHIBITOR; BINIMETINIB; COBIMETINIB; DABRAFENIB; ENCORAFENIB; MITOGEN ACTIVATED PROTEIN KINASE; PEMBROLIZUMAB; PLACEBO; PROTEIN TYROSINE KINASE; TRAMETINIB; VASCULOTROPIN; VASCULOTROPIN RECEPTOR; VEMURAFENIB; BRAF PROTEIN, HUMAN; PROTEIN KINASE INHIBITOR;

BRAIN METASTASIS; CANCER CHEMOTHERAPY; CANCER CONTROL; CANCER GROWTH; CANCER PROGNOSIS; COMBINATION DRUG THERAPY; CUTANEOUS MELANOMA; DRUG EFFICACY; DRUG INTERMITTENT THERAPY; DRUG RESPONSE; DRUG SAFETY; DRUG SCREENING; DRUG SENSITIVITY; DRUG TOLERABILITY; ENZYME ACTIVATION; ENZYME INHIBITION; FEVER; GENE MUTATION; HUMAN; HYPERKERATOSIS; IMMUNOTHERAPY; KERATOACANTHOMA; LONG TERM SURVIVAL; METASTATIC MELANOMA; MOLECULARLY TARGETED THERAPY; MONOTHERAPY; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROGRESSION FREE SURVIVAL; PROTEIN TARGETING; QUALITY OF LIFE; REVIEW; SKIN CARCINOMA; SKIN TOXICITY; ANTAGONISTS AND INHIBITORS; DRUG EFFECTS; GENETICS; IMMUNOLOGY; IMMUNOMODULATION; MELANOMA; MULTIMODALITY CANCER THERAPY; MUTATION;

COMBINED MODALITY THERAPY; HUMANS; IMMUNOMODULATION; IMMUNOTHERAPY; MELANOMA; MUTATION; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS B-RAF;

EID: 84987597549     PISSN: 15233790     EISSN: 15346269     Source Type: Journal    
DOI: 10.1007/s11912-016-0554-5     Document Type: Review

References (50)

1. Siegel R, Miller K, Ahmedin J. Cancer statistics, 2016. CA Cancer J Clin. 2016;66:7–30.
2. Chapman PB, Einhorn LH, Meyers ML, Saxman S, Destro AN, Panageas KS, et al. Phase III multicenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma. J Clin Oncol. 1999;17:2745–51.
3. Davies H, Bignell GR, Cox C, et al. Mutations of the BRAF gene in human cancer. Nature. 2002;417:949–54.
4. Lopez-Bergami P. The role of mitogen- and stress-activated protein kinase pathways in melanoma. Pigment Cell Melanoma Res. 2011;24:902–21.
5. Chapman PB, Hauschild A, Robert C, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med. 2011;364:2507–16.
6. Hauschild A, Grob JJ, Demidov LV, et al. Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, openlabel, phase 3 randomised controlled trial. Lancet. 2012;380:358–65.
7. Larkin J, Del Vecchio M, Ascierto PA, Krajsova I, Schachter J, Neyns B, et al. Vemurafenib in patients with BRAF(V600) mutated metastatic melanoma: an open-label, multicenter, safety study. Lancet Oncol. 2014;15(4):436.
8. Lacouture ME, Duvic M, Hauschild A, Prieto VG, Robert C, Schadendorf D, et al. Analysis of dermatologic events in vemurafenib-treated patients with melanoma. Oncologist. 2013;18(3):314–22.
9. Carnahan J, Beltran PJ, Babij C, et al. Selective and potent Raf inhibitors paradoxically stimulate normal cell proliferation and tumor growth. Mol Cancer Ther. 2010;9:2399–410.
10. Boussemart L, Routier E, Mateus C, et al. Prospective study of cutaneous side effects associated with the BRAF inhibitor vemurafenib: a study of 42 patients. Ann Oncol. 2013;24:1691–7.
11. Carlos G, Anforth R, Clements A, Menzies AM, Carlino MS, Chou S, et al. Cutaneous toxic effects of BRAF inhibitors alone and in combination with MEK inhibitors for metastatic melanoma. JAMA Dermatol. 2015;151(10):1103–9.
12. Paraiso KH, Fedorenko IV, Cantini LP, et al. Recovery of phosphor-ERK activity allows melanoma cells to escape from BRAF inhibitor therapy. Br J Cancer. 2010;102:1724–30.
13. Long G, Stroyakovskiy D, Gogas H, Levchenko E, de Braud F, Larkin J, et al. Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicenter, double-blind, phase 3 randomised controlled trial. Lancet. 2015;386(9992):444–51. Compared to BRAF monotherapy, dual targeted therapy with BRAF + MEK inhibition demonstrates improvement in both PFS and OS.
14. Robert C, Karaszewska B, Schachter J, Rutkowski P, Machiewicz A, Stroiakovski D, et al. Improved overall survival in melanoma with combined Dabrafenib and Trametinib. N Engl J Med. 2015;372:30–9.
15. Ascierto PA, McArthur G, Dreno B, Larkin J, Liszkay G, Maio M, et al. coBRIM: a phase 3, double-blind, placebo-controlled study of vemurafenib versus vemurafenib + cobimetinib in previously untreated BRAFV600 mutation-positive patients with unresectable locally advanced or metastatic melanoma (NCT01689519). J Transl Med. 2015;13 Suppl 1:O4.
16. Grob JJ, Amonkar M, Karaszewska B, Schachter J, Dummer R, Machiewicz A, et al. Comparison of dabrafenib and trametinib combination therapy with vemurafenib monotherapy on health-related quality of life in patients with unresectable or metastatic cutaneous BRAF Val600-mutation-positive melanoma (COMBI-v): results of a phase 3, open-label, randomised trial. Lancet Oncol. 2015;16(13):1389–98. doi:10.1016/S1470-2045(15)00087-X.
17. Larkin JMG, Yan Y, McArthur G, Ascierto PA, Liszkay G, Maio M, Mandala M, et al. Update of progression-free survival (PFS) and correlative biomarker analysis from coBRIM: Phase III study of cobimetinib (cobi) plus vemurafenib (vem) in advanced BRAF-mutated melanoma. JCO, 2015 ASCO annual Meeting (May 29 – June 2, 2015). 2015; 33: Abstract 9006.
18. Sullivan R, Weber J, Patel SP, Dummer R, Miller WH, Cosgrove D, et al. A phase Ib/II study of BRAF inhibitor (BRAFi) encorafenib (ENCO) plus MEK inhibitor (MEKi) binimetinib (BINI) in cutaneous melanoma patients naïve to BRAFi treatment. JCO, 2015 ASCO annual Meeting (May 29 – June 2, 2015). 2015;33: Abstract 9007.
19. Bozic I, Reiter JG, Allen B, et al. Evolutionary dynamics of cancer in response to targeted combination therapy. eLife. 2013;2, e00747.
20. Johnson D, Flaherty K, Weber J, Infante J, Kim K, Kefford R, et al. Combined BRAF (dabrafenib) and MEK inhibition (trametinib) in patients with BRAFV600-mutant melanoma experiencing progression with single-agent BRAF inhibitor. J Clin Oncol. 2014;32:3697–704.
21. Ribas A, Gonzalez R, Pavlick A, et al. Combination of vemurafenib and cobimetinib in patients with advanced BRAFV600-mutated melanoma: a phase 1b study. Lancet Oncol. 2014;15:954–65.
22. Nathanson KL, Martin AM, Wubbenhorst B, Greshock J, Letrero R, O´Day S, et al. Tumor genetic analyses of patients with metastatic melanoma treated with the BRAF inhibitor dabrafenib (GSK2118436). Clin Cancer Research. 2013;19(17): 4868–78.
23. McArthur GA, Chapman PB, Robert C, et al. Safety and efficacy of vemurafenib in BRAFV600E and BRAFV600K mutation-positive melanoma (BRIM-3): extending follow-up of a phase 3, randomized open-label study. Lancet Oncol. 2014;15:323–32.
24. Zheng G, Tseng LH, Chen G, Haley L, Illei P, Gocke C, et al. Clinical detection and categorization of uncommon and concomitant mutations involving BRAF. BMC Cancer. 2015;15:779.
25. Kim KB, Kefford R, Pavlick AC, Infante JR, Ribas A, Sosman JA, et al. Phase II study of the MEK1/MEK2 inhibitor Trametinib in patients with metastatic BRAF-mutant cutaneous melanoma previously treated with or without a BRAF inhibitor. J Clin Oncol. 2013;31(4):482–9.
26. Shi H, Hugo W, Kong X, Hong A, Koya R, Moriceau G, et al. Acquired resistance and clonal evolution in melanoma during BRAF inhibitor therapy. Cancer Discov. 2014;4(1):80–93.
27. V600E/K amplifications, BRAF splice variants, and various non-MAPK alterations.
28. Hugo W, Shi H, Sun L, Piva M, Song C, Kong X, et al. Non-genomic and immune evolution of melanoma acquiring MAPKi resistance. Cell. 2015;162(6):1271–85.
29. Kim KB, Flaherty KT, Chapman PB, et al. Pattern and outcome of disease progression in phase I study of vemurafenib in patients with metastatic melanoma (MM). J Clin Oncol. 2011;29(Suppl):8519.
30. Long G, Weber J, Infante J, Kim K, Daud A, Gonzalez R, et al. Overall survival and durable responses in patients with BRAF V600-Mutant metastatic melanoma receiving dabrafenib combined with trametinib. J Clin Oncol. 2016;34(8):871–8. Characteristics of long-term responders to BRAF-targeted therapy include normal LDH, earlier-stage melanoma, and fewer metastatic sites.
31. Joseph RW, Elassaiss-Schaap J, Wolchok JD, et al. Baseline tumor size as an independent prognostic factor for overall survival in patients with metastatic melanoma treated with anti-PD-1 monoclonal antibody MK-3475. J Clin Oncol 32, 2014 (abstr 3015).
32. Atkins Michael. Dabrafenib and trametinib followed by ipilimumab and nivolumab or ipilimumab and nivolumab followed by dabrafenib and trametinib in treating patients with stage III-IV BRAFV600 melanoma. In: Clinicaltrials.gov. Bethesda (MD): National Library of Medicine (US). 2000–2016. Available from URL https://clinicaltrials.gov/ct2/show/NCT02224781.
33. Larkin J, Chiarion-Sileni V, Gonzalez R, Grob JJ, Cowey CL, Lao C, et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med. 2015;373:23–34.
34. Wolchok J, Chiarion-Sileni V, Gonzalez R, Rutkowski P, Jacques Grob J, Cowey CL, Lao C, et al. Updated results from a phase III trial of nivolumab (NIVO) combined with ipilimumab (IPI) in treatment-naïve patients with advanced melanoma. J Clin Oncol 34, 2016 (suppl; abstr 9505). Presented at ASCO Annual Meeting 2016. Chicago, IL. June 3–7, 2016.
35. Jakob JA, Bassett Jr RL, Ng CS, et al. NRAS mutation status is an independent prognostic factor in metastatic melanoma. Cancer. 2012;118:4014–23.
36. Long GV, Trefzer U, Davies MA, Kefford RF, Ascierto PA, Chapman PB, et al. Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicenter, open-label, phase II trial. Lancet Oncol. 2012;13(11):1087–95. The BREAK-MB study demonstrated response rates from 6.7% - 39.2% with dabrafenib for previously treated brain metastases, indicating this is a reasonable treatment for patients with CNS lesions not candidates for surgery or SRS.
37. Dummer R, Goldinger SM, Turtschi CP, et al. Vemurafenib in patients with BRAF(V600) mutation-positive melanoma with symptomatic brain metastases: final results of an open-label pilot study. Eur J Cancer. 2014;50:611–21.
38. Margolin K, Ernstoff MS, Hamid O, et al. Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial. Lancet Oncol. 2012;13:459–65.
39. Frederick DT, Piris A, Cogdill AP, Cooper ZA, Lezcano C, Ferrone CR, et al. BRAF inhibition is associated with enhanced melanoma antigen expression and a more favorable tumor microenvironment in patients with metastatic melanoma. Clin Cancer Res. 2013;19(5):1225–31. In the pre-clinical setting, tissue samples treated with BRAF inhibition demonstrate a more favorable microenvironment for immunotherapy.
40. Hu-Lieskovan S, Mok S, Homet Moreno B, Tsoi J, Robert L, Goedert L, et al. Improved antitumor activity of immunotherapy with BRAF and MEK inhibitors in BRAF(V600E) melanoma. Sci Transl Med. 2015;7(272):279ra41. doi:10.1126/scitranslmed.aaa4691.
41. Ribas A, Hodi FS, Callahan M, Konto C, Wolchok J. Hepatotoxicity with combination of Vemurafenib and Ipilimumab. N Engl J Med. 2013;368:1365–6.
42. Puzanov I. Combining targeted and immunotherapy: BRAF inhibitor dabrafenib (D) +/− MEK inhibitor trametinib (T) in combination with ipilimumab (Ipi) for V600E/K mutation-positive unresectable or metastatic melanoma (MM). J Transl Med. 2015 (Suppl 1): K8.
43. BRAF-associated melanoma clinical trials. My Cancer Genome. https://www.mycancergenome.org/clinicaltrials/?disease=melanoma&gene=BRAF. Last accessed: May 21, 2016.
44. Hamid O, et al. Preliminary clinical safety, tolerability and activity of atezolizumab (anti-PD-L1) combined with Zelboraf in BRAFv600 metastatic melanoma. Presented at the Society for Melanoma Research 2015 International Congress; November 18–21, 2015; San Francisco, CA.
45. Ribas A, Hodi S, Lawrence D, Atkinson V, Starodub A, Carlino M, et al. Pembrolziumab (pembro) in combination with dabrafenib (D) and trametinib (T) for BRAF-mutant advanced melanoma: Phase 1 KEYNOTE-022 study. J Clin Oncol 34, 2016 (suppl; abstr 3014). Presented at American Society of Clinical Oncology Conference; June 5–7, 2016; Chicago, IL.
46. 47. Atkins Michael. Dabrafenib and trametinib followed by ipilimumab and nivolumab or ipilimumab and nivolumab followed by dabrafenib and trametinib in treating patients with stage III-IV BRAFV600 melanoma. In: Clinicaltrials.gov. Bethesda (MD): National Library of Medicine (US). 2000–2016. Available from URL https://clinicaltrials.gov/ct2/show/NCT02224781.
47. Menzies A, Long G. Systemic treatment for BRAF-mutant melanoma: where do we go next? Lancet Oncol. 2014;15:e371–81.
48. BRAF inhibitor, LGX818, utilizing a pulsatile schedule in patients with Stage IV or unresectable Stage III melanoma characterized by a BRAFV600 mutation. https://clinicaltrials.gov/ct2/show/NCT01894672. Last accessed: May 24, 2016.
49. Dabrafenib and Trametinib in treating patients with stage III-IV BRAF mutant melanoma that cannot be removed by surgery. https://clinicaltrials.gov/ct2/show/NCT02196181. Last accessed: 11 July 2016.
50. Tolcher AW, Patnaik A, Papadopoulos KP, Rasco DW, Becerra CR, Allred AJ, et al. Phase I study of the MEK inhibitor trametinib in combination with the AKT inhibitor afuresertib in patients with solid tumors and multiple myeloma. Cancer Chemother Pharmacol. 2015;75(1):183–9.